🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

95 results for “Base” Clear

  1. A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SATRALIZUMAB AS MONOTHERAPY OR IN ADDITION TO BASELINE THERAPY IN PATIENTS WITH MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISEASE (MOGAD)

    Hoffmann-La Roche

    Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)

    phase 3 other active

    1 trial

  2. A Phase III, Randomized, Double-Blind Study of Tiragolumab Plus Atezolizumab Compared with Placebo Plus Atezolizumab in Participants with Completely Resected Stage IIB, IIIA, or Select IIIB, PD-L1 Positive, Non-Small Cell Lung Cancer who have received Adjuvant Platinum-Based Chemotherapy

    Hoffmann-La Roche

    Non-Small Cell Lung Cancer

    phase 3 other active

    1 trial

  3. A Study Evaluating Pharmacokinetic similarity between ABP 234 and Keytruda® (pembrolizumab) in Subjects with Early-stage Non-squamous Non-small Cell Lung Cancer as Adjuvant Treatment Following Resection and Platinum-based Chemotherapy

    Amgen

    Early-stage Non-squamous Non-small Cell Lung Cancer

    phase 3 other active

    1 trial

  4. ABIRATERONE , DEGARELIX , Niraparib - capsule - 100 mg, RELUGOLIX , Niraparib tosylate monohydrate+ abiraterone acetate - Film coated tablet- 159.40 mg (eq. 100mg base)+ 500mg, Placebo for Niraparib, Prednison acis 5 mg, Tabletten, Niraparib tosylate monohydrate + abiraterone acetate - Film coated tablet- 79.90 mg (eq. 50mg base)+ 500mg, TECHNETIUM (99MTC) COMPOUNDS, -, Abiraterone acetate - tablet - 250 mg

    Janssen-Cilag International N.V.

    Metastatic Prostate Cancer

    phase 3 small molecule active

    1 trial

  5. BOTOX 50 UNITÉS ALLERGAN, poudre pour solution injectable, SODIUM CHLORIDE

    Pari Pharma GmbH

    Adults aged at least 18 years with painful base-of-thumb osteoarthritis

    phase 3 small molecule active

    1 trial

  6. Household-based water treatment with NADCC tablets

    United Therapeutics Europe Ltd

    Diarrhoea

    phase 3 other completed

    1 trial

  7. Internet-based smoking treatment

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Dependence

    phase 3 other completed

    1 trial

  8. Irinotecan liposome、5-Fluorouracil、Leucovorin

    Jian Li

    Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy

    phase 3 small molecule completed

    1 trial

  9. Niraparib - capsule - 100 mg, Niraparib tosylate monohydrate+ abiraterone acetate - Film coated tablet- 159.40 mg (eq. 100mg base)+ 500mg, Placebo for ABIRATERONE ACETATE, -, Niraparib, PREDNISOLONE , ABIRATERONE , Placebo for Niraparib, Abiraterone acetate - tablet - 250 mg, Placebo for NIRAPARIB / ABIRATERONE ACETATE 50/500 mg FDC, Niraparib tosylate monohydrate + abiraterone acetate - Film coated tablet- 79.90 mg (eq. 50mg base)+ 500mg, Prednison acis 5 mg, Tabletten, Placebo for NIRAPARIB / ABIRATERONE

    Janssen-Cilag International N.V.

    Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

    phase 3 small molecule active

    1 trial

  10. Niraparib tosylate monohydrate + abiraterone acetate - Film coated tablet- 79.90 mg (eq. 50mg base)+ 500mg, Capivasertib, NUBEQA 300 mg film-coated tablets, CABAZITAXEL, ENZALUTAMIDE , DAROLUTAMIDE , ABIRATERONE , ABIRATERONE ACETATE, APALUTAMIDE , RADIUM (223RA) DICHLORIDE , DOCETAXEL , OLAPARIB, Capivasertib, Niraparib tosylate monohydrate+ abiraterone acetate - Film coated tablet- 159.40 mg (eq. 100mg base)+ 500mg, BAY 1841788

    The George Institute

    Prostate Cancer

    phase 3 small molecule active

    1 trial

  11. OFOBA : Opioid-Free versus Opioid-Based Anaesthesia for free-flap reconstruction surgery of the breast: A phase III multicentric randomized controlled study.

    The George Institute

    Anaesthesia during free flap reconstruction surgery of the breast.

    phase 3 other active

    1 trial

  12. PEMBROLIZUMAB , Matching placebo, EIK1001 solution for injection 1.0 mg/mL free base equivalent

    Eikon Therapeutics

    Advanced Melanoma

    phase 3 small molecule active

    1 trial

  13. PLACEBO, IMFINZI 50 mg/mL concentrate for solution for infusion., MYCOPHENOLATE MOFETIL, INFLIXIMAB, DOMVANALIMAB

    AstraZeneca AB

    The target population of interest in this study is participants with locally advanced (Stage III), unresectable NSCLC, whose tumours express PD L1 TC ≥ 1% as assessed by a central reference laboratory using the VENTANA PD-L1 (SP263) IHC assay, and who did not progress after definitive platinum based cCRT.

    phase 3 small molecule active

    1 trial

  14. Placebo for Opdivo, Rubraca 200 mg film-coated tablets, Rubraca 250 mg film-coated tablets, Rubraca 300 mg film-coated tablets, OPDIVO 10 mg/mL concentrate for solution for infusion., Placebo for Rubraca

    pharmaand GmbH

    Ovarian epithelial cancer, Malignant peritoneal neoplasm, advanced (FIGO stage III-IV), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer (who responded to front-line platinum-based chemotherapy), Fallopian tube cancer

    phase 3 small molecule active

    1 trial

  15. Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-small Cell Lung Cancer Stage IIIA

    phase 3 small molecule terminated

    1 trial

  16. RBC transfusion based on different protocols

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Transfusion Related Complication

    phase 3 other active

    1 trial

  17. Rusfertide 45mg, Rusfertide 60mg, Rusfertide 30mg, Rusfertide 10mg, Rusfertide 20mg, Placebo to Match PTG-300 for Injection. Formulation (lyophilized powder) is based upon that of PTG-300 for Injection, with the drug substance omitted.

    Protagonist Therapeutics, Inc

    Polycythemia Vera

    phase 3 small molecule active

    1 trial

  18. TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, PLACEBO

    AstraZeneca AB

    Histologically documented non-small cell lung cancer of predominantly non-squamous pathology who present with locally advanced, unresectable (Stage III) disease, whose tumor tissue has EGFR exon 19 deletions or exon 21 (L858R) substitution mutations, either alone or in combination with other EGFR mutations, as detected by cobas® EGFR Mutation Test v2 (Roche Diagnostics) and whose disease has not progressed following definitive platinum-based chemoradiation.

    phase 3 small molecule active

    1 trial

  19. The MIN-102 Placebo is supplied as an oral suspension with similar appearance to MIN-102 drug product. MIN-102 placebo oral suspension is packaged in an amber glass bottle with filled volume based on the required clinical dose.

    Minoryx Therapeutics S.L.

    Cerebral adrenoleukodystrophy (cALD)

    phase 3 small molecule active

    1 trial

  20. Ustekinumab Dose Based on BSA and Body Weight

    Janssen Cilag International NV

    Colitis, Ulcerative

    phase 3 small molecule completed

    1 trial

  21. Voucher-Based Reinforcement Therapy

    BRIGHT MINDS BIOSCIENCES INC.

    Substance-related Disorders

    phase 3 other completed

    1 trial

  22. mitomycin C-based hyperthermic intraperitoneal chemotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma

    phase 3 other active

    1 trial

  23. strengths-based case management

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    phase 3 other completed

    1 trial

  24. A Phase II, Randomized, Multicenter, Double-Blind, Controlled Study of Tobemstomig Plus Platinum-Based Chemotherapy versus Pembrolizumab Plus Platinum-Based Chemotherapy in Patients with Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    Hoffmann-La Roche

    Previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC)

    phase 2 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources